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Autosomal-recessive congenital sodium diarrhea (CSD) is characterized by perinatal onset of a persistent watery diarrhea with nonpro-
portionally high fecal sodium excretion. Defective jejunal brush-border Naþ/Hþ exchange has been reported in three sporadic patients,
but the molecular basis of the disease has not been elucidated. We reviewed data from a large cohort of CSD patients (n¼ 24) and distin-
guished CSD associated with choanal or anal atresia, hypertelorism, and corneal erosions—i.e., a syndromic form of CSD—occurring in
ten families from an isolated form—i.e., classic CSD—presenting in seven families. Patients from both groups have a high risk of
mortality due to immediate electrolyte imbalances and complications from long-term parenteral nutrition in the ﬁrst years of life,
but survivors can eventually adapt to partial or complete enteral nutrition. A genome-wide SNP scan was applied and identiﬁed a homo-
zygous c.5931G/A splicing mutation in SPINT2, encoding a Kunitz-type serine-protease inhibitor, in one extended kindred with
syndromic CSD. The same mutation and four distinct, homozygous or compound heterozygous mutations (p.Y163C, c.1A/T,
c.337þ2T/C, c.553þ2T/A) were identiﬁed in all syndromic patients. No SPINT2 mutations were found in classic-CSD patients.
SPINT2 mutations were associated with loss of protein synthesis or failure to inhibit the serine protease trypsin in vitro. We delineate
syndromic CSD as a distinct disease entity caused by SPINT2 loss-of-function mutations. SPINT2 mutations might lead to an excess
of yet unknown serine protease activity in affected tissues.Introduction
Congenital sodium diarrhea (CSD [MIM 270420]) is
a rare, inherited diarrhea of infancy, ﬁrst described in
1985.1,2 A diagnosis of CSD is made on the ﬁndings of
a life-threatening secretory diarrhea, severe metabolic
acidosis, and hyponatremia secondary to extraordinarily
high fecal losses of sodium, with low or normal excre-
tion of urinary sodium, in the absence of infectious,
autoimmune, and endocrine causes. Intestinal biopsies
from CSD patients generally reveal mild to moderate
villus atrophy and do not show any speciﬁc histological
changes, allowing differentiation from microvillus inclu-
sion disease and congenital tufting enteropathy.1–3 Addi-
tional features, such as choanal atresia, anal atresia,
corneal erosions, and hypertelorism, have been observed
in association with CSD.3 Patients are initially dependent
on parenteral nutrition in order to acquire adequate
caloric and ﬂuid intake and allow for normal growth
and development. Prolonged parenteral nutrition is188 The American Journal of Human Genetics 84, 188–196, Februaryfrequently complicated by bacteremia and liver disease
and can confer a poor quality of life. Single-case reports
have shown that CSD patients can be weaned
completely from parenteral nutrition in childhood with
oral sodium citrate supplementation while watery diar-
rhea persists.1,2
Defective jenunal brush-border Naþ/Hþ exchange was
demonstrated in three unrelated patients with CSD.1,4,5
However, the pathogenesis of CSD remains poorly under-
stood, and the molecular basis of the disease has not
been identiﬁed. We previously considered and excluded
an involvement of known jejunal genes coding for Naþ/Hþ
exchangers (NHEs), in our study of a family with ﬁve
affected children displaying autosomal-recessive inheri-
tance of CSD,3 and Zachos et al. excluded such involve-
ment using sequence analysis in one patient.6
We have now studied a large cohort of CSD patients to
deﬁne the clinical phenotype and applied the positional-
candidate approach to deﬁne the molecular basis of this
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Material and Methods
Patients
Written informed consent from the parents or legal guardians of
all patients was obtained, and the study was performed in accor-
dance with national ethical standards on human experimenta-
tion. Patients fulﬁlling the following criteria were given a diagnosis
of CSD:3 Newborns presenting with (a) intractable diarrhea that
did not cease while infants were receiving nothing by mouth
and (b) voluminous alkaline stools (fecal pH > 7.5, normal,
6.5–7.4) containing high concentrations of sodium (fecal Naþ >
70 mmol/l, normal, 20–35 mmol/l), leading to hyponatremia
(plasma Naþ < 130 mmol/l, normal, 136–147 mmol/l) and
profound metabolic acidosis (plasma pH < 7.30, normal, 7.35–
7.45). Light- and/or electron-microscopic examinations revealed
villus atrophy with no features of microvillus inclusion disease
or tufting enteropathy. Anal atresia occurred in two patients.
There was otherwise no radiological evidence of any anatomic
anomaly in the gastrointestinal tract, and laboratory parameters
indicating chronic infection or autoimmune disease were nega-
tive. Endocrine causes of secretory diarrhea were excluded by
normal plasma concentrations of thyroid hormones, thyroid-
stimulating hormone, vasoactive intestinal peptide, calcitonin,
gastrin, and prostaglandin E2. Also, plasma concentrations of
adrenocorticotropic hormone, cortisol, and 17-OH-progesterone
were normal, excluding adrenogenital syndrome. Negative sweat
tests excluded cystic ﬁbrosis.
Linkage and Mutation Analysis
We carried out a genome-wide linkage scan using the Affymetrix
GeneChip XbaI 10K 2.0 SNP arrays,7,8 using DNA samples from
two affected and 11 unaffected individuals from one kindred
(Figure 1A, Table 1 [family 1]).3 We obtained parametric multi-
point LOD-score calculations and haplotypes with the Allegro
program,9 using an autosomal-recessive, fully penetrant model.
We selected ten genes from the candidate region (SCN1B [MIM
600235], KRTDAP, TMEM147, ATP4A [MIM 137216], RBM42,
COX6B [MIM 124089], SPINT2 [MIM 605124], KCNK6 [MIM
603939], FBXO17 [MIM 609094], SNRPA [MIM 182285]) on the
basis of putative function and expression patterns for mutation
analysis. The coding regions and splice sites were PCR ampliﬁed
and directly sequenced in the proband from the original family
(primer sequences for SPINT2 are shown in Supplemental Data,
available online, and data referring to the other genes are available
from the authors). The sequencing reactions were analyzed on the
ABI 3100 DNA sequencer, with BigDye terminator mix (Applied
Biosystems, Vienna, Austria). The probands from 16 additional
families were screened for SPINT2mutations by direct sequencing.
Relatives were tested for variants detected in a proband. A panel of
DNA samples from anonymous healthy controls was analyzed for
the presence of sequence variants. Highly degraded DNA samples
extracted from formalin-ﬁxed parafﬁn-embedded tissue from two
patients of the original family were sequenced with PCR primers
SPINT2 7F and SPINT2 7R3, generating an 89 bp PCR fragment
encompassing the splice site found mutated in the proband.
Multiplex ligation-dependent probe ampliﬁcation (MLPA) was
performed in samples without mutations, with the MRC-Holland
SALSA MLPA P300-A1 control kit, and newly designed synthetic
probes targeting three of the seven SPINT2 exons (Supplemental
Data). Probes were designed according to the recommendations
of MRC-Holland (Amsterdam).The AmericSPINT2mRNA Analysis and Transient Transfection
mRNAwas extracted from blood samples with the PAXgene Blood
RNA Kit (PreAnalytiX, QIAGEN, Vienna, Austria) and reversely
transcribed into cDNA with the SuperScript III First-Strand
Synthesis System (Invitrogen, Lofer, Austria). SPINT2 primers c4f
and 7R were used for ampliﬁcation and direct sequencing of an
aberrantly spliced fragment in the patient with the c.5931G/A
mutation. SPINT2 cDNA from patients harboring the p.Y163C or
c.5931G/A mutation and from a control was ampliﬁed with
the use of primers TopoF and V5R. For cloning of c.1A/T, the
forward primer used was TopoM1F (Supplemental Data). The
PCR products were cloned into the pcDNA3.2/V5/GW/D-Topo
vector (Invitrogen, Leogang, Austria) so that C-terminally fused
V5 epitopes could be obtained. The constructs were veriﬁed by
DNA sequencing, and COS-7 cells grown to ~70% conﬂuency
were transfected via electroporation. Cells were lysed 48 hr after
transfection by the addition of 0.5 ml radioimmunoassay precipi-
tation buffer (RIPA) without protease inhibitors. After 20 min
incubation on ice, cells were scratched off with a rubber
policeman, and the postnuclear supernatant was prepared by
centrifugation at 12.000 3 g for 30 min. Supernatants were
concentrated on Amicon 10.000 Da molecular-weight-cutoff
membrane ultraﬁltration tubes (Millipore, Vienna, Austria).
Puriﬁcation of Recombinant Spint2 Proteins
Fusion proteins were puriﬁed from cell lysates by immunoafﬁnity
chromatography with the use of amonoclonal mouse anti-V5 anti-
body (ABP Afﬁnity BioReagents, Golden, CO, USA) immobilized to
NHS-activated sepharose (1 m HiTrap column, GE Healthcare,
Vienna, Austria), according to the manufacturer’s directions.
Protein extractswere loaded in lysis buffer onto the immunoafﬁnity
column and eluted in 0.05 M glycine pH 2.7, containing 0.15 M
NaCl and 0.1% Triton X, after extended washing. Elution fractions
were neutralized by addition of saturated Tris HCl pH 8.9 to a ﬁnal
concentration of 2%. Anti-V5 immunoreactivity in elution frac-
tions was assayed by western blotting: equal amounts of protein
(50 mg) were separated by 12.5% SDS-PAGE10 and blotted onto
PVDF membranes (GE Healthcare, Vienna, Austria), and SPINT2-
V5 fusion protein was detected with mouse anti-V5 antibody at
1:500 dilution in 0.3%skimmedmilk in PBST (Invitrogen, Leogang,
Austria) and with a secondary horseradish-peroxidase-labeled goat
anti-mouse antibody (DAKO, Vienna, Austria) at 1:1000 dilution.
Immunological complexes were visualized by enhanced chemilu-
minescence with the use of an ECL-kit (GE Healthcare, Vienna,
Austria) and a CCD camera (Chemidoc XRS, BioRad, Munich,
Germany).
Trypsin-Activity Assays
The trypsin inhibitory activity of SPINT2 WT and SPINT2 Y163C
proteins was tested by trypsin-mediated para-nitroaniline (pNA)
release from the artiﬁcial substrate Tos-Gly-Pro-Lys-para-nitroani-
line. After preincubation of 4mg/ml trypsin with equal amounts
of immunoafﬁnity-puriﬁed SPINT2WTor SPINT2 Y163C in 5mM
morpholinoethanesulfonic acid (MES), pH 6.5, the reactions were
mixed with artiﬁcial substrate at a ﬁnal concentration of 100 mM,
and the absorbance at 405 nm was monitored over 10 min in
a Beckmann DU64 spectrophotometer equipped with a cuvette
heated at 37C. Trypsin activity was calculated from the slope of
the linear increase in absorbance over time. The experiments
were performed in quadruplicate, and results were analyzed with
the Mann-Whitney U Test.an Journal of Human Genetics 84, 188–196, February 13, 2009 189
Figure 1. Genetic Mapping, an Analysis of the c.593-1G/A Splice-Site Mutation, and Clinical Findings in CSD
(A) Pedigree of CSD family no. 1. Numbers below symbols indicate individuals whose DNA was included in the genome-wide SNP-linkage
scan, with the exception of patients 671 and 209, whose DNA samples were subsequently shown to harbor the SPINT2 mutation identified
in the proband (arrow), and with the exception of individual 15.190 The American Journal of Human Genetics 84, 188–196, February 13, 2009
Results
Homozygosity mapping in a large kindred (Figure 1A)
identiﬁed a single genomic region of extended homozy-
gosity (Figure 1B) and haplotypes consistent with the
inheritance of the mutation from a common ancestor in
the proband and affected sib. The critical interval spanned
6.754 Mb on chromosome 19q13, with boundaries set
between SNPs rs1363364 and rs2317314 by two recombi-
nants (data not shown). Among the 220 genes contained
in the interval (National Center for Biotechnology Infor-
mationmap build 36.2), ten genes were considered as plau-
sible candidates (see Material and Methods).
Sequencing revealed no mutations in nine candidate
genes, whereas analysis of the seven SPINT2 exons and
splice sites identiﬁed ahomozygous c.593-1G/Amutation
affecting a canonical splice site in the index case (Figure1A).
A faint amount of an aberrant fragment of SPINT2 RNA
from leukocytes of this patient, compared with controls,
was seen byRT-PCR. Sequencing this cDNA species revealed
the activation of a cryptic splice site upstream in intron 6
and the abnormal inclusion of 72 nucleotides in the
message (Figure 1C). This fragment was not ampliﬁed in
cDNA frommutation carriers (Figure 1C), suggesting prefer-
ential transcription from the normal allele or, rather,
nonsense-mediated mRNA decay of additional abnormal
RNA species resulting from this splice-site mutation, thus
leading to loss of normal gene expression.
A SPINT2-mutation analysis was subsequently per-
formed in all available DNA samples from our series of
CSD patients. The clinical baseline characteristics and
results of mutation analysis of patients are summarized
in Table 1. The same homozygous c.593-1G/A mutation
was identiﬁed in an apparently unrelated CSD patient orig-
inating from the same rural area in Austria as the original
family. Four distinct germline SPINT2 mutations were
detected in eight additional families (Table 1 and Supple-
mental Data). Each of these mutations segregated with
the disease status in families, and none was present among
188 Austrian and 100 Swedish controls. Six apparently
unrelated families of Swedish origin and an Amish patient
(originating from Alsace-Lorraine) shared a c.488A/G
(p.Y163C) mutation. Genotyping eight SNPs within and
ﬂanking SPINT2 in these families provided evidence
for a common haplotype, suggesting a founder effect
(data not shown). The mutated tyrosine 163 is highlyThe Americconserved within the conserved catalytic Kunitz domain
(Figure 2).
SPINT2 mutations were detected in ten of 17 families
(group 1). Neither mutations nor copy-number changes
(Supplemental Data) were present in the remaining seven
families (group 2), leading us to establish a genotype-
phenotype correlation: We noted that malformations,
dysmorphic features, or corneal erosions were recorded in
14 of 16 patients from families with SPINT2 mutations
(Figure 1D); i.e., a syndromic form of CSD was present.
In contrast, malformations or corneal disease were not
recorded in any of eight CSD patients from group 2, i.e.,
indicating classic CSD. Nine of 16 patients from group 1
have had cyclically recurrent, painful punctate epithelial
corneal lesions. Local diclofenac treatment once a day pro-
longed relapse intervals. Peripheral neovascularization of
the corneas, as well as hyperopia and astigmatism, were
found in two patients. One of these patients has a reduced
visual acuity of 0.5 in both eyes at the age of 12 years.
A history of polyhydramnios is a frequent ﬁnding in both
CSD groups. Patients from both groups were dependent on
total parenteral nutrition in the ﬁrst years of life and
frequentlydied fromrelatedcomplications.However, survi-
vors who could be partially or completely weaned from
parenteral nutritionwere observed in both groups (Table 1).
To investigate the functional consequences of the SPINT2
missense alterations, as well as the c.593-1G/A mutation,
we expressed recombinant WT and mutant proteins in
COS-7 cells through transient transfection. Immunoblot-
ting of cell extracts showed two bands matching the pre-
dicted molecular weight of SPINT2, with and without
cleaved signal peptide for WT and p.Y163C mutation. No
immunoreactivity was visible in SPINT2-overexpressing
cells encoding the start-codon mutation (c.1A/T) or the
intronicvariantc.593-1G/A(Figures3Aand3B).No immu-
noreactivity for the SPINT2 fusion protein could be detected
in concentrated media from SPINT2-overexpressing cells,
suggesting that SPINT2 is retained intracellularly in vitro
(data not shown). Compared with WT, Cys-163-mutated
SPINT2 caused a signiﬁcant decrease (p< 0.05) in the ability
to inhibit trypsin, a prototype serine protease (Figure 3C).
Discussion
Here, we present clinical and genetic evidence to delineate
a syndromic form of CSD distinct from the originally(B) A LOD score above 3.0 indicates a single region on chromosome 19 that is significantly linked to the disease in this family. The graph
represents a parametric LOD score on the y axis in relation to genetic position on the x axis. Human chromosomes are concatenated from
p-ter (left) to q-ter (right) on the x axis, and the genetic distance is given in cM.
(C) Left: sequence chromatograms show the mutation c.593-1G/A (black arrows) in homozygous and heterozygous state in genomic
DNA samples from individuals 343 and 924, respectively. Individual 924 also shows heterozygosity for c.598G/C (p.V200L,
rs17850978, red arrow) on the genomic level. The c.598G/C variant and the c.593-1G/A mutation reside on different alleles, as
revealed by haplotype analysis (not shown). Right: cDNA sequencing reveals apparent homozygosity for the c.598G/C variant in
individual 924. Only an aberrant transcript containing 72 nucleotides of intron 6 is obtained from the patient with the homozygous
c.593-1G/A mutation.
(D) Facial characteristics of patients CD1(1), A2HE(1), and 343. Note hypertelorism, long philtrum, sparse hair, and photophobia.an Journal of Human Genetics 84, 188–196, February 13, 2009 191
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splicing
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cted none -Table 1. Clinical and Molecular Findings of CSD Families
Family No., Ancestry Patient Identifier
Sex, Parental
Consan-guinity Polyhy-dramnios
Age, Outcome, Current
Treatment
Malformations and
Dysmorphological
Features
SPINT2 Nu
Alteration
1, Austria3 343 M, yes unknown died at 13 mo bilateral choanal atresia,
hypertelorism, corneal
erosions
c.593-1G/
homozygo
334 F, yes unknown died at 7 mo hypertelorism, corneal
erosions
c.593-1G/
homozygo
671 M, yes unknown died at 6 mo not recorded c.593-1G/
homozygo
15 F, yes unknown died at 10 mo double kidney no DNA sa
209 F, yes unknown died at 4 mo bilateral choanal atresia,
cleft palate, aortic-valve
hamartoma
c.593-1G/
homozygo
2, Austria A2HE(1) F, yes no 3 yrs, alive, EN hypertelorism, corneal
erosions
c.593-1G/
homozygo
3, Sweden S1H(1) F, no unknown died at 6 mo unilateral choanal atresia,
broad thumbs, corneal
erosions
c.488A/
S1H(2) F, no no died at 14 mo bilateral choanal atresia,
extra digit on right hand,
low-sitting thumbs,
corneal erosions
c.488A/
4, Sweden S2L(1) M, no unknown 13 yrs, alive, PPN corneal erosions c.488A/
5, Sweden S3SH(1) F, yes no 12 yrs, alive, PPN not recorded c.488A/
6, Sweden S4EB(1) F, no no 12 yrs, alive, PPN bilateral choanal atresia,
corneal erosions
c.337þ2T
c.488A/
heterozyg
7, Sweden S5AA(1) M, no yes died at 31 mo bilateral choanal atresia c.488A/
S5AA(2) F, no no died at 11 mo bilateral choanal atresia,
anal atresia
no DNA
8, Sweden S6TJ(1) F, no no died at 22 mo bilateral choanal atresia,
corneal erosions
c.488A/
c.553þ2T
heterozyg
9, The Netherlands N1P(1) M, no no died at 9 yrs bilateral choanal atresia,
long philtrum, anteverted
nares, short and
brittle hair, mild
psychomotor delay
c.1A/T,
compound
10, Canada—Amish CD1(1) F, yes yes 5 mo, alive, TPN bilateral choanal atresia,
imperforate anus,
rectovaginal fistula,
corneal erosions, short
and brittle hair
c.488A/
11, UK1 UK1P F, no yes 29 yrs, alive, EN none none dete
12, UK5 UK2B M, no yes 20 yrs, alive, EN none none dete
13, Algeria F1B F, yes no 21 mo, EN none none dete
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.Thedescribed, classic-CSD type.1,2 Choanal atresia, hypertelor-
ism, and corneal erosions are particularly frequent in
syndromic CSD, and anal atresia occurred in two of
16 patients. Although both types of the disease can be fatal
in the neonatal period and in the ﬁrst years of life as a result
of dehydration, severe electrolyte imbalances, and long-
term complications of parenteral nutrition, we present
mounting evidence that patients from both groups can
eventually adapt to partial or complete enteral nutrition
during childhood. A successful outcome appears to be inde-
pendent of the disease-causing SPINT2 genotype, as ref-
lected by our identiﬁcation of six syndromic patients with
a SPINT2 c.593-1G/A mutation. Of these patients, ﬁve
died before their 13th month of life, from complications
of parenteral nutrition, and a sixth patient could beweaned
from parenteral nutrition during her 3rd year of life. This
was the only syndromic-CSD patient in whom at the age
of 18 months oral sodium (2.5 mmol/kg/d) and potassium
citrate (1.0 mmol/kg/d) supplementation was introduced.
A similar oral therapy regimen was considered beneﬁcial
inpatientswithclassicCSD.1,2 Earlydiagnosis andadequate
treatment might therefore confer a favorable long-term
prognosis in syndromic and classic CSD. Alternatively,
either adverse or beneﬁcial effects of genetic modiﬁers
might ultimately determine the outcome of these diseases.
The positional candidate approach led to the identiﬁca-
tion of a total of ﬁve distinct splicing and missense muta-
tions in homozygous or compound-heterozygous state in
SPINT2, encoding a Kunitz-type serine-protease inhibitor,
in syndromic-CSD families, but not in classic-CSD families.
SPINT2, also known as placental bikunin and hepatocyte
growth factor activator inhibitor type 2 (HAI-2), has been
shown to be a potent inhibitor of a number of serine prote-
ases, such as pancreatic trypsin, plasmin, kallikrein,11 and
hepatocyte growth factor activator,12 in vitro. Serine prote-
ases carry out several physiological and cellular functions,
ranging from degradation and digestive processes to
protein processing and tissue remodeling.13 Loss of SPINT2
protein expression or its function would therefore be
expected to increase the activity of target serine proteases.
Indeed, we showed that three SPINT2 mutations cause
either a decrease in the ability to inhibit trypsin or unde-
tectable amounts of SPINT2 protein in vitro.We also found
that SPINT2 proteins were not secreted in vitro, consistent
with the prediction of a transmembrane domain (residues
198–221). This suggests either insertion of SPINT2 into the
plasma membrane, with the Kunitz domains localizing
extracellularly, or an intracellular role of the protein.
Together, our data show that syndromic CSD is caused by
SPINT2 loss of function. The physiological target of
SPINT2 and the molecular pathology caused by SPINT2
deﬁciency are currently unknown.
CSD is a secretory diarrhea characterized by hyponatre-
mia due to enormous fecal losses of large amounts of
sodium, metabolic acidosis, and no evidence of primary
structural abnormalities in the intestinal epithelium. Intes-
tinal absorption of sodium occurs along the entire gut andAmerican Journal of Human Genetics 84, 188–196, February 13, 2009 193
is provided by a variety of transport mechanisms: co-trans-
porters, i.e., proteins that manage the simultaneous
absorption of Naþ with nutrients such as glucose14 or
amino acids;15 coupled exchangers, such as the Naþ/Hþ-
and Cl/HCO3-transport proteins, allowing electroneutral
absorption of NaCl;16 and the amiloride-sensitive epithe-
lial sodium channel (ENaC [MIM 600760]).17,18
In syndromic CSD, SPINT2 mutations can affect proteo-
lytic activity in the functional regulation of intestinal
epithelial absorption or secretion of sodium. Possible
targets include the membrane-bound extracellular serine
proteases, the channel-activating proteases (CAP)/prosta-
sin [MIM 600823]19 and TMPRSS2 [MIM 602060],20 and
the intracellular protease furin21 all of which have been
shown to regulate ENaC activity through limited proteol-
ysis. In other studies, however, the serine-protease inhib-
itor aprotinin19 and a recombinant, secreted form of
Figure 2. Conservation of the SPINT2
p.Y163C Mutation
(A) Alignment of multiple human Kunitz
domains from different proteins. The mut-
ated tyrosine is invariantly conserved
within the highly conserved catalytic
Kunitz domain.
(B) Alignment of known and predicted
SPINT2 orthologs shows high evolutionary
conservation of this mutated tyrosine
residue.
SPINT222 blocked ENaC-mediated
Naþ transport in vitro. A direct role
of SPINT2 as an inhibitor of serine
proteases involved in the activation
of ENaC thus appears unlikely.
Alternatively, the serine protease
dipeptidyl peptidase IV (DPPIV
[MIM 126141]) has been suggested
to affect the activity of NHE3 (sodium/hydrogen
exchanger 3, SLC9A3 [MIM 182307]), which localizes to
the apical epithelial plasma membrane and contributes
largely to NaCl absorption.6,23 Lack of inhibition of DPPIV
would be expected to lead to decreased NaCl absorption.
Notably, NHE3-knockout mice recapitulate the intestinal
human-CSD phenotype,24 and a defect of sodium/proton
exchange as a cause of CSD was suggested in three patients
with the classic type.1,4We did not identify a SPINT2muta-
tion in one patient with defective NHE,1 compatible with
the possibility that CSD can result from different mecha-
nisms and consistent with genetic-locus heterogeneity.
SPINT2 might be the ﬁrst serine-protease inhibitor to be
involved in an intestinal disease. SPINT2 is apparently not
being secreted, and its deﬁciency is not associated with
overt histological changes of the intestine, contrasting
with, e.g., deﬁciency of serine-protease inhibitors KazalFigure 3. Expression and Trypsin-Inhibition Analysis of WT and Mutated SPINT2 Proteins
(A) Expression of SPINT2 WT and c.1A/T-, p.Y163C-, and c.593-1G/A-mutated proteins in COS-7 cells.
(B) Purification of SPINT2 WT and Cys-163-mutated protein showed no quantitative or qualitative differences.
(C) Trypsin activity was significantly less inhibited in COS-7 cells transfected with the Y163C SPINT2 mutant as compared with WT protein.194 The American Journal of Human Genetics 84, 188–196, February 13, 2009
type 5 (SPINK5 [MIM 605010]) and type 1 (SPINK1 [MIM
167790]). SPINK5 deﬁciency causes severe abnormalities
of cell-layerdesquamationand inﬂammation incongenital,
autosomal-recessive dermatosis associated with Netherton
syndrome,25 and heterozygous and homozygous SPINK1
mutations are associated with chronic pancreatitis.26
The fact that complete loss of SPINT2 protein causes
severe clefting of the embryonic ectoderm and early intra-
uterine death in mice27 supports the idea that either some
residual SPINT2 activity is retained in patients or other
proteins can compensate for loss of SPINT2 in humans.
Notably, the presence of choanal and intestinal atresia
implicates SPINT2 activity in human prenatal develop-
ment. However, choanal and intestinal atresia might result
from a secondary phenomenon after normal embryonal
development, as a result of a disturbance of the optimal
surface-liquid volume, which is maintained by the regu-
lated transport of sodium and chloride across the airway
epithelium.28 This situation might be similar to that of
disturbed CFTR activity causing primary or secondary apla-
sia of the vas deferens prenatally.29
In conclusion, we have characterized syndromic CSD as
a new entity, which differs from classic CSD by loss-of-
functionmutations in SPINT2 and the presence of congen-
ital malformations and dysmorphological features or
corneal erosions. The determination of the molecular basis
of syndromic CSD and the recent identiﬁcation of the
genetic defects of the differential diagnoses, microvillus
inclusion disease [MIM 251850]30 and tufting enterop-
athy,31 will facilitate rapid diagnosis of patients and
contribute to the counseling of affected families. The
consequences of alterations in SPINT2 function on the
intestinal absorption of sodium and human development
in syndromic CSD remain to be elucidated.
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